65,437 trials
Smoking Cessation · HIV Infections
Primary: Percentage of Participants With Biochemically Verified 7-day Point Prevalence Smoking/Tobacco Abstinence at 12 Weeks — 2; 4 Participants
Dermatitis, Atopic · Eczema
Primary: Double-blind Induction Period: Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) 75 (>=75% Reduction From Baseline in EASI Score) at Week 16…
Bile Duct Carcinoma · Gallbladder Carcinoma · Pancreatic Ductal Adenocarcinoma
Primary: Number of Participants That Had Desaturation Episodes of SpO2 <90% — 0; 3; 26; 27 Participants
Adolescent Behavior · Emergency Department · Abuse Physical
Primary: Participant Acceptability Ratings for Healthcare Provider Discussions on Relationships in ED-Heart Intervention Arm — 39; 6 Participants — p=.622
Cervical Cancer
Primary: Disease-free Survival (Percentage of Participants Alive Without Disease) — 86.4; 82.1; 76.2; 76.9 percentage of participants — p=0.56
Temperature Change, Body
Primary: Skin Temperature — 31.18; 31.21; 31.1; 31.93 degrees celsius
Obstructive Pulmonary Disease · Cardiomyopathies · Heart Failure
Primary: Improvement in Sleep Quality Using Pittsburgh Sleep Quality Index — -3.6; -1.6 units on a scale
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) — -1.9; -1.8; -2.1; -1.1 Percentage-point of HbA1c — p=0.0002
Sjogren's Syndrome · Dry Eye
Primary: Mean Change in Cornea Staining — -1.78 units on a scale
Gonorrhoea
Primary: Rectal Mucosal IgG Concentrations (Geometric Mean Titers [GMT]) Against N. Gonorrhoeae Outer Membrane Vesicle (OMV) Antigen Ng1291 — 0.07; 0.072; 0.089; 0.097 titer
Fuchs' Endothelial Corneal Dystrophy
Primary: Central Corneal Endothelial Cell Density (ECD) at Week 12 — 530.86; 468.02; 228.05 cells/mm2 — p=0.0065
Aphakia
Primary: Mean Binocular Photopic Best Corrected Distance Visual Acuity (BCDVA) at 3 to 6 Months (90 to 180 Days) Postoperatively After Second Eye Implant — -0.028; -0.062 logMAR
Carcinoma, Squamous Cell of Head and Neck · HPV Positive Oropharyngeal Squamous Cell Carcinoma · Hypopharyngeal Cancer
Primary: Maximum Tolerated Dose of Cisplatin — 30 mg/m2
Chronic Pain
Primary: Change in the Brief Pain Inventory (BPI) Interference Score From Baseline, Over the 12-month Follow-up Period. — 4.8; 4.5; 5.2 score on a scale — p=0.031
Cardiac Pacemaker, Artificial · Cardiac Rhythm Disorder · Bradycardia
Primary: Percentage of Participants Free From Aveir DR System-Related Complications at 3-months — 90.3 percentage of participants — p=<0.0001